In a report released yesterday, Whitney Ijem from Canaccord Genuity reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), with a ...

Fintel reports that on March 31, 2025, Redburn Atlantic initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a ...

Analysts' ratings for Alnylam Pharmaceuticals ALNY over the last quarter vary from bullish to bearish, as provided by 27 ...

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price increased by Stifel Nicolaus from $300.00 to ...

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...

Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...

Buying $100 In ALNY: If an investor had bought $100 of ALNY stock 20 years ago, it would be worth $3,328.04 today based on a ...

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price upped by research analysts at Scotiabank from ...

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced moderated poster presentations of new data from the landmark ...

CAMBRIDGE, Mass., April 01, 2025--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company ...

An in-depth analysis of recent analyst actions unveils how financial experts perceive Alnylam Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and ...